What Klipal Codéine Treats: Main Uses and Benefits

This combination medication is applied across domains where additional symptomatic support is needed when symptoms become too disruptive.

Symptom Relief and Patient Support

This medication is used for managing symptoms related to physical discomfort that have become intense or disruptive. It plays a role in managing conditions presenting with moderate to severe pain, such as dental pain, post-operative discomfort, discomfort from sprains, or pain associated with acute injuries. The medicine is commonly used when short-term symptomatic assistance is needed for conditions characterized by periods of heightened symptoms.

It contributes to general well-being during symptomatic phases and may assist patients with managing acute episodes.

“It assists with maintaining comfort during symptomatic periods, helping to address the overall symptom burden.”

It is also relevant for easing symptoms related to systemic imbalance, such as fever, that often occurs alongside painful conditions. By providing supportive relief from both the pain and the associated fever, it may assist with easing the overall symptom load.

---

Quick Fact: Relief for Pronounced Pain and Fever

---

Regulatory References

1. European Medicines Agency (EMA) guidance on codeine-containing medicines

Klipal Codéine, a combination of acetaminophen and codeine, is subject to specific regulatory eligibility rules concerning age, physiological status, and underlying health conditions.

Contraindicated Populations

The medicine must not be used in several patient groups, as defined by official regulatory bodies:

• Children younger than 12 years of age for any indication.
• Children younger than 18 years of age following tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome.
• Patients known to be CYP2D6 ultra-rapid metabolisers.
• Women during breastfeeding (Lactation).
• Patients with significant respiratory depression, severe bronchial asthma, or known paralytic ileus.

Restricted and Conditional Use

Use is restricted or conditional in certain populations:

Population	Eligibility Status (Regulatory Labeling)
Adolescents 12–18	Not recommended if respiratory function is compromised.
Pregnancy	Avoid use unless benefits clearly outweigh risks, due to risk of neonatal withdrawal syndrome.
Severe Renal Impairment	Requires a minimum dose interval of at least 8 hours.
Older Adults	Use requires caution; dosage reduction may be necessary.

Eligibility is also affected by conditions like head injury or increased intracranial pressure, where the medicine should be used with caution.

Klipal Codéine, a combination product containing paracetamol and codeine, has documented interactions primarily relating to the codeine component's effects on the central nervous system (CNS) and its metabolic pathway.

Documented Interaction Restrictions

Interacting Product Category	Regulatory Constraint
CNS Depressants (including alcohol, benzodiazepines, and certain sedatives, hypnotics, and anxiolytics)	Concomitant use may result in profound sedation, respiratory depression, coma, and death. Prescribing should be limited to the minimum required dosage and duration when alternative treatments are inadequate. The combination with alcohol must be avoided.
Monoamine Oxidase Inhibitors (MAOIs)	Concomitant use is contraindicated, including within 14 days of discontinuing an MAOI, due to the risk of enhanced respiratory depression.
CYP2D6 Inhibitors (e.g., quinidine, certain antidepressants)	Co-administration may decrease the formation of codeine's active metabolite, morphine, which can lead to reduced analgesic efficacy. Close monitoring or avoidance is required.
Serotonergic Drugs (including SSRIs, SNRIs)	Concomitant use carries a risk of Serotonin Syndrome (a potentially serious condition).

Population-Specific Interaction Notes

Codeine is contraindicated in individuals who are known to be CYP2D6 ultra-rapid metabolizers, as this genetic variation leads to the rapid and excessive conversion of codeine into morphine, raising the risk of toxicity, including life-threatening respiratory depression. The product is also generally not recommended for use in breastfeeding mothers.

Klipal Codéine contains two distinct pharmacologically active components: codeine and paracetamol (acetaminophen).

Codeine functions as a prodrug that undergoes O-demethylation, primarily catalyzed by the hepatic cytochrome P450 isoenzyme CYP2D6, to yield the active metabolite, morphine.

Morphine acts as an agonist at central opioid receptors, predominantly the mu-opioid receptor ( MOR), which is a G-protein coupled receptor. Activation of the MOR initiates an intracellular cascade involving the inhibition of adenylyl cyclase, leading to a decrease in intracellular cyclic adenosine monophosphate ( cAMP). This results in the hyperpolarization of neuronal cell membranes and the inhibition of neurotransmitter release, modulating signal transmission within the central nervous system. Downstream consequences include systemic modulation of afferent neuronal signaling.

Paracetamol's mechanism is not fully elucidated but involves the inhibition of cyclooxygenase ( COX) enzymes, specifically COX-3 in the central nervous system, and potential interaction with the serotonergic descending pain pathway. This action modifies prostaglandin synthesis and modulates signaling within the nervous system.

How to Use Klipal Codéine: Official Administration Guidelines

Klipal Codéine is administered according to specific protocols which govern the route, frequency, and maximum limits for the fixed-dose combination of Paracetamol and Codeine. This guidance ensures the drug is used strictly within its labeled parameters.

---

Administration Scope

Category	Official Instruction
Route of Administration	The medication is approved for oral intake.
Dosing Schedule	A minimum interval of 6 hours must be observed between administrations.
Maximum Dosing	The maximum duration of treatment must not exceed 3 consecutive days.
Maximum Daily Limits	The dose must not exceed 4 administrations per 24 hours, nor 240 mg Codeine or 4000 mg Paracetamol.

---

Procedural and Population-Specific Rules

Administration of the tablet requires it to be swallowed whole with a glass of water. For the 600 mg/50 mg strength, the score line is intended only to facilitate swallowing, not to divide the dose for therapeutic use.

Population-specific instructions mandate adjustments to the standard regimen:

• Pediatric Use: The medication is contraindicated for children under 12 years of age.
• Older Adults: The initial dosage should typically be reduced by half compared to the standard adult dose.
• Renal Impairment: For severe impairment, the minimum dosing interval must be extended to at least 8 hours.

Research evidence / Overview of Studies for Klipal Codéine

The research base for the combination of Acetaminophen and Codeine (Klipal Codéine) consists primarily of short-term clinical trials and subsequent reviews. These studies have been used in research exploring how symptoms change over time and have primarily focused on measuring changes in pain intensity over short, defined periods. Evidence contributes to understanding symptom patterns, but findings describe group patterns, not personal outcomes.

---

Evidence for Managing Acute, General Pain

Research examining this combination for managing general, moderate to severe acute pain was studied for various causes not relieved by non-opioid medications alone. The research focused on outcomes related to physical discomfort and utilized aggregated data from many randomized controlled trials (RCTs) and systematic reviews. Studies observed responses over defined time intervals, often the first few hours after taking a single dose. These findings describe patterns observed in the studies when comparing the combination to a placebo or to taking only the non-opioid ingredient.

The evidence for this research context is generally classified as moderate. However, research exploring short-term symptom changes was associated with high heterogeneity, meaning that results varied across studies due to differences in patient groups, the types of pain being studied, and the doses used. Furthermore, follow-up durations were limited, and there is limited information for long-term outcomes regarding this general acute pain research.

---

Evidence from Studies of Post-Operative Pain Relief

Research examining this medicine for acute post-operative pain has historically been a strong area of focus, utilizing numerous single-dose, placebo-controlled clinical trials. The intent of the research was to quantify short-term outcomes describing episodic or acute changes in pain levels immediately after procedures such as dental or general outpatient surgery.

The data show patterns related to short-term changes in pain scores, with reports describing measurements of changes in acute pain scores over the first four to six hours post-dose. Because these single-dose studies are highly structured and follow a consistent design, the evidence structure for this immediate, short-term research scenario is often classified as high when comparing the combination to a placebo, suggesting consistency in the patterns of measured outcomes across the different study arms.

Despite the relative consistency in the acute, short-term findings, the evidence provides limited information on outcomes related to multi-day dosing regimens relevant to extended post-operative observation periods. Studies do not provide sufficient insight into what might occur during extended observation periods for post-surgical recovery.

---

Research Structure for Chronic Pain Conditions

The combination was evaluated in the context of chronic, non-cancer pain, specifically focusing on certain joint conditions like osteoarthritis. This research involved short-term multi-dose RCTs in specific adult populations. The trials reported how symptoms evolved in the observed populations over defined, limited treatment periods.

However, the evidence base for chronic pain is considered low because sample sizes were modest, and follow-up durations were limited (often only a few weeks). Findings were mixed across the few available studies, suggesting certainty remains low.

What remains uncertain is the performance of the combination over long periods. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding the sustained research of this combination for chronic conditions.

Key Studies & References

1. Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults (Cochrane Review)
2. Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials
3. Safety and efficacy of the combination Acetaminophen-Codeine in the treatment of pain of different origin (European Review for Medical and Pharmacological Sciences)

Common questions about Klipal Codéine (FAQ)

---

Q: Is Klipal Codéine the same as just taking codeine?

No, according to official product information, Klipal Codéine is a fixed-dose combination medicine. It contains two active ingredients: paracetamol (also known as acetaminophen) and codeine. Taking a medicine that only contains codeine would mean the paracetamol component is missing, which is a key part of how this combination is intended to manage pain.

---

Q: How long does the effect of Klipal Codéine usually last?

Official product information indicates that the effects of the codeine component typically last for approximately four to six hours. Regulatory documents describe a minimum interval of six hours between administrations, which is consistent with the duration of effect.

---

Q: Is it possible to become tolerant to the effects of Klipal Codéine?

Yes, official guidance from health authorities indicates that if this medicine is used regularly for an extended period, the body can develop tolerance to the codeine component. This indicates that tolerance may develop, a pattern where increasing amounts of the medicine may be needed to have the same effect. Regulatory documents issue strong warnings against extended use.

---

Q: Is Klipal Codéine safe for patients with high blood pressure?

Regulatory guidance suggests that individuals taking medicines for high blood pressure should exercise caution when reviewing codeine-containing products. Codeine has the potential to interact with certain blood pressure medications. Official product information emphasizes that a prescriber should be fully informed about all concurrent medications being taken, including treatments for conditions like high blood pressure.

---

Q: Does Klipal Codéine interact with grapefruit juice or other foods?

Official drug information and general drug-food interaction monographs sometimes advise that grapefruit juice may be an interacting product with some medicines. The most complete information on potential food and beverage interactions is typically detailed in the specific patient information leaflet provided with the medicine.

---

Q: What should I do if I miss a scheduled dose of Klipal Codéine?

General instructions found in regulatory sources state that if a dose is missed, it can be taken when remembered. However, if it is near the time for the next dose, the missed dose is typically skipped. Official guidance strictly notes that taking two doses simultaneously to compensate for a missed dose is not recommended.

---

Q: Can Klipal Codéine be taken on an empty stomach?

Official guidance often suggests taking codeine-containing products with or just after a meal or snack. This approach is often related to reducing the potential for common gastrointestinal side effects, such as nausea or stomach upset.

---

Q: Are there any reported interactions with herbal supplements and Klipal Codéine?

Regulatory documents indicate that it is not possible to assure that herbal remedies and supplements are safe because they do not undergo the same testing as prescription medicines. Specific supplements, such as St. John’s wort, may interact with the drug’s components. Official documents note that prescribers should always be informed about all herbal supplements being taken, as this allows for a full review of potential interactions.

---

Q: Why are there different strengths of Klipal Codéine available?

The availability of different strengths of Klipal Codéine (such as 500 mg/30 mg or 600 mg/50 mg) is defined in the official qualitative and quantitative composition sections of regulatory documents. This range allows prescribers to determine the lowest effective dose necessary to adequately manage the patient’s specific level of pain.

---

Q: Can Klipal Codéine interfere with laboratory blood tests?

Yes, regulatory and monitoring guidance for the components of this medicine indicate that taking it may potentially affect the results of certain laboratory tests. Due to the potential for unwanted effects, official documents suggest that a doctor may need to monitor a patient’s progress using blood tests while this medicine is being used.

---

Q: Is Klipal Codéine available as a generic medicine?

The active ingredient combination of Acetaminophen and Codeine is widely available as a generic medicine in many countries. Generic availability is approved through regulatory pathways and listed in official drug databases.

The storage and disposal of Klipal Codéine (Acetaminophen/Codeine) are strictly regulated to maintain product quality and prevent the misuse or accidental exposure of this opioid-containing medicine.

Official Storage Requirements

Requirement	Description
Temperature	Store at room temperature, typically below 25 C (77F). Keep from freezing and away from excess heat.
Protection	Keep the medicine in its original container, tightly closed, and protect from light and moisture.
Child Safety	Mandatory instruction: Keep out of the sight and reach of children and pets in a secure location.

Disposal Instructions

Because this is a narcotic-containing medicine, proper disposal of unused or expired tablets is mandatory. The preferred method is to use a drug take-back program or mail-back envelope. If a take-back option is not readily available, national health authorities may recommend flushing certain high-risk opioids, or, alternatively, mixing them with an undesirable substance (like dirt or coffee grounds) and sealing the mixture in a bag before disposal in the household trash.